» Articles » PMID: 29113181

MicroRNA Profiling and Bioinformatics Analyses Reveal the Potential Roles of MicroRNAs in Chordoma

Overview
Journal Oncol Lett
Specialty Oncology
Date 2017 Nov 9
PMID 29113181
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Chordoma is a rare aggressive bone tumor arising from remnants of the notochord, and patients with chordoma have a poor prognosis. However, the unique expression profiles of microRNAs (miRNAs/miRs) and their downstream signaling pathways in chordoma remain incompletely characterized. The aim of the present study was to delineate the global miRNA expression profile and associated signaling networks in chordoma. miRNA profiling was performed on chordoma and fetal notochord tissues. Differentially expressed miRNAs in chordoma were analyzed using microarrays with hierarchical clustering analysis. The target genes of the differentially expressed miRNAs were predicted, and Gene Ontology (GO) and pathway analyses were performed for the intersecting genes. A total of 42 miRNAs were significantly dysregulated in chordoma compared with that in fetal nucleus pulposus tissues. The expression of hsa-miR-21-3p, hsa-miR-150-5p, hsa-miR-1290 and hsa-miR-623 were validated using the reverse transcription-quantitative polymerase chain reaction. On the basis of the intersection predicted by three databases (Targetscan, microRNA.org and PITA), 10,292 potential miRNA targets were identified. Bioinformatic analyses suggested that these dysregulated miRNAs and their predicted targets were functions of signaling pathways in cancer, the mitogen-activated protein kinase signaling pathway, regulation of actin cytoskeleton, focal adhesion and endocytosis. In particular, human (hsa-)miR-185-5p was identified as a crucial miRNA in chordoma development via the Wnt signaling pathway. The results of the present study provide a comprehensive expression and functional profile of differentially expressed miRNAs associated with chordoma. This profile may serve as a potential tool for biomarker and therapeutic target identification in patients with chordoma.

Citing Articles

MicroRNA‑1224 inhibits cell proliferation by downregulating CBX3 expression in chordoma.

Xia W, Huang J, Sun C, Shen F, Yang K Oncol Lett. 2024; 27(6):262.

PMID: 38646496 PMC: 11027112. DOI: 10.3892/ol.2024.14395.


Activation of Wnt Pathway Suppresses Growth of MUG-Chor1 Chordoma Cell Line.

Sisli H, Hayal T, Senkal S, Bulut E, Kiratli B, Asutay A Cell Biochem Biophys. 2023; 81(4):823-837.

PMID: 37751039 DOI: 10.1007/s12013-023-01178-5.


DNA methylation, combined with RNA sequencing, provide novel insight into molecular classification of chordomas and their microenvironment.

Baluszek S, Kober P, Rusetska N, Wagrodzki M, Mandat T, Kunicki J Acta Neuropathol Commun. 2023; 11(1):113.

PMID: 37434245 PMC: 10337070. DOI: 10.1186/s40478-023-01610-0.


miR-1290 inhibits chordoma cell proliferation and invasion by targeting Robo1.

Wang B, Zhang K, Chen H, Lu J, Wu G, Yang H Transl Cancer Res. 2022; 8(2):542-551.

PMID: 35116786 PMC: 8797437. DOI: 10.21037/tcr.2019.03.13.


LncRNA NONHSAT114552 Sponges miR-320d to Promote Proliferation and Invasion of Chordoma Through Upregulating NRP1.

Zhang K, Liu Z, Tang Y, Shao X, Hua X, Liu H Front Pharmacol. 2021; 12:773918.

PMID: 34721048 PMC: 8548433. DOI: 10.3389/fphar.2021.773918.


References
1.
Tamborini E, Virdis E, Negri T, Orsenigo M, Brich S, Conca E . Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas. Neuro Oncol. 2010; 12(8):776-89. PMC: 2940683. DOI: 10.1093/neuonc/noq003. View

2.
Zhang K, Chen H, Zhang B, Sun J, Lu J, Chen K . Overexpression of Raf-1 and ERK1/2 in sacral chordoma and association with tumor recurrence. Int J Clin Exp Pathol. 2015; 8(1):608-14. PMC: 4348883. View

3.
McMaster M, Goldstein A, Bromley C, Ishibe N, Parry D . Chordoma: incidence and survival patterns in the United States, 1973-1995. Cancer Causes Control. 2001; 12(1):1-11. DOI: 10.1023/a:1008947301735. View

4.
Fuchs B, Dickey I, Yaszemski M, Inwards C, Sim F . Operative management of sacral chordoma. J Bone Joint Surg Am. 2005; 87(10):2211-6. DOI: 10.2106/JBJS.D.02693. View

5.
Casali P, Stacchiotti S, Sangalli C, Olmi P, Gronchi A . Chordoma. Curr Opin Oncol. 2007; 19(4):367-70. DOI: 10.1097/CCO.0b013e3281214448. View